ATE542138T1 - Her-2-bindungsantagonisten - Google Patents

Her-2-bindungsantagonisten

Info

Publication number
ATE542138T1
ATE542138T1 AT01912833T AT01912833T ATE542138T1 AT E542138 T1 ATE542138 T1 AT E542138T1 AT 01912833 T AT01912833 T AT 01912833T AT 01912833 T AT01912833 T AT 01912833T AT E542138 T1 ATE542138 T1 AT E542138T1
Authority
AT
Austria
Prior art keywords
seq
amino acids
polypeptide
sequence
monoclonal antibody
Prior art date
Application number
AT01912833T
Other languages
English (en)
Inventor
Gail Clinton
William Henner
Adam Evans
Original Assignee
Univ Oregon Health Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oregon Health Sciences filed Critical Univ Oregon Health Sciences
Application granted granted Critical
Publication of ATE542138T1 publication Critical patent/ATE542138T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT01912833T 2000-02-16 2001-02-16 Her-2-bindungsantagonisten ATE542138T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/506,079 US7625859B1 (en) 2000-02-16 2000-02-16 HER-2 binding antagonists
PCT/US2001/005327 WO2001061356A1 (en) 2000-02-16 2001-02-16 Her-2 binding antagonists

Publications (1)

Publication Number Publication Date
ATE542138T1 true ATE542138T1 (de) 2012-02-15

Family

ID=24013084

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01912833T ATE542138T1 (de) 2000-02-16 2001-02-16 Her-2-bindungsantagonisten

Country Status (7)

Country Link
US (4) US7625859B1 (de)
EP (1) EP1257822B1 (de)
JP (1) JP2004501605A (de)
AT (1) ATE542138T1 (de)
AU (1) AU4157501A (de)
CA (1) CA2400473A1 (de)
WO (1) WO2001061356A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541214B1 (en) 1998-11-13 2003-04-01 Oregon Heath Science University N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7396810B1 (en) 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
WO2001001748A2 (en) 1999-07-02 2001-01-11 Genentech, Inc. Peptide compounds that bind her2
CA2511816A1 (en) * 2002-12-26 2004-07-22 Cemines, Inc. Methods and compositions for the diagnosis, prognosis, and treatment of cancer
EP2463299A3 (de) 2003-03-05 2012-10-17 Dendreon Corporation Zusammensetzungen und Verfahren unter Anwendung von Polypeptiden mit alternativem Leserahmen zur Behandlung von Krebs und Infektionskrankheiten
TWI472339B (zh) * 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
EP2430443B1 (de) * 2009-05-14 2018-06-27 Pierian Holdings, Inc. Biomarker zur bestimmung der empfindlichkeit von brustkrebszellen gegenüber einer auf her2 gerichteten therapie
US9427458B2 (en) 2010-07-22 2016-08-30 Consejo Nacional De Investigaciones Cientificas Y Tecnicas, Conicet Methods for inhibiting cancer cell proliferation
KR101258144B1 (ko) 2011-07-22 2013-04-30 한양대학교 산학협력단 Ｅｃｍ１ 항체를 함유하는 항암용 조성물
CN105985435B (zh) * 2015-01-30 2019-10-15 嘉和生物药业有限公司 全人源her2抗体的突变抗体及其编码基因和应用
HUE051246T2 (hu) 2015-05-30 2021-03-01 Molecular Templates Inc Deimmunizált shigatoxin alegység vázak és azokat tartalmazó, sejthez irányító molekulák
KR20200143634A (ko) 2018-04-17 2020-12-24 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 스캐폴드를 포함하는 her2-표적화 분자
WO2023168426A1 (en) 2022-03-03 2023-09-07 Enosi Therapeutics Corporation Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof
WO2024186690A2 (en) 2023-03-03 2024-09-12 Enosi Therapeutics Corporation Oligo-trap fusion proteins (ofps) and uses thereof

Family Cites Families (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US633169A (en) * 1899-06-17 1899-09-19 Alexander Hazard Bottle-stopper.
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
EP0119528B1 (de) 1983-03-11 1992-05-13 Sloan-Kettering Institute For Cancer Research Monoklonale Antikörper gegen menschliche Nierenkrebsantigene und Verfahren
EP0171407B1 (de) 1984-01-30 1993-11-18 Imperial Cancer Research Technology Limited Verbesserungen an wachstumsfaktoren
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US7838216B1 (en) 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US4933284A (en) * 1986-05-07 1990-06-12 Uop Regenerable dialkylaminoalkyl cellulose support matrix for immobilizing biologically active materials
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US5206152A (en) 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
CA1341191C (en) 1988-04-18 2001-02-27 Robert Allan Weinberg Detection of neu gene expression and products
EP0412118A4 (en) 1988-04-29 1991-09-25 Barry M. Fell Reinforced thermoplastic honeycomb structure
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
US6207645B1 (en) * 1989-03-21 2001-03-27 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
EP0737750B1 (de) 1989-03-21 2003-05-14 Vical, Inc. Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DK0474727T3 (da) 1989-05-19 1998-01-12 Genentech Inc HER2 ekstracellulært domæne
US5705157A (en) 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
EP0444181B2 (de) 1989-08-04 2010-11-24 Bayer Schering Pharma Aktiengesellschaft Äusserliche domäne von c-erbb-2:gp75
EP0487587A1 (de) 1989-08-18 1992-06-03 Chiron Corporation Rekombinante retroviren um vektorkonstruktionen an zielzellen zu liefern
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
EP0494135B1 (de) 1989-09-29 1996-04-10 Oncogene Science, Inc. p100 "neu" menschlisches Protein and Verwendung dieses Proteins zum Nachweis von preneoplasmatischen- oder neoplasmatischen beim Menschen
US5149855A (en) * 1989-12-26 1992-09-22 Mitsubishi Rayon Co., Ltd. Process for racemizing optically active carboxylic acid esters
AU7316391A (en) 1990-01-25 1991-08-21 State of Oregon acting by and through the The State Board of Higher Education on Behalf of the Oregon Health Sciences University, The Detection of a characteristic antigen from carcinoma in body fluids
NZ237464A (en) 1990-03-21 1995-02-24 Depotech Corp Liposomes with at least two separate chambers encapsulating two separate biologically active substances
DE69126430T2 (de) * 1990-04-06 1997-09-18 Univ Pennsylvania Ligand für das neu-gen-produkt
EP0459942B1 (de) 1990-05-10 1995-02-22 Ciba-Geigy Ag Tinten
US5578482A (en) 1990-05-25 1996-11-26 Georgetown University Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses
US5874528A (en) 1990-05-25 1999-02-23 Georgetown University Binding peptides which interact with ligand growth factors of the epidermal growth factor receptor and erbB-2 receptor
US5149655A (en) 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
DK0563278T3 (da) 1990-12-20 2000-08-21 Dana Farber Cancer Inst Inc Regulering af geneekspression med ioniserende stråling
US5571894A (en) * 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992014748A1 (en) 1991-02-22 1992-09-03 American Cyanamid Company Identification of a novel human receptor tyrosine kinase gene
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US5580858A (en) * 1991-06-10 1996-12-03 Alberta Research Council Immunosuppressive and tolerogenic modified Lewisx compounds
CA2111006C (en) 1991-06-21 2008-04-08 Andrew D. Boyd A novel receptor-type tyrosine kinase and use thereof
WO1993003769A1 (en) 1991-08-20 1993-03-04 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES Adenovirus mediated transfer of genes to the gastrointestinal tract
CA2096417C (en) 1991-08-22 2000-10-10 Sarah S. Bacus Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
JPH07506242A (ja) 1992-01-09 1995-07-13 ヘルシンキ　ユニバーシティ　ホルディング　リミテッド Ｔｉｅ，新規内皮細胞受容体チロシンキナーゼ
US6331302B1 (en) 1992-01-22 2001-12-18 Genentech, Inc. Protein tyrosine kinase agonist antibodies
JPH07503372A (ja) 1992-01-23 1995-04-13 バイカル・インコーポレイテッド 生体外遺伝子導入
JPH05271294A (ja) * 1992-01-24 1993-10-19 Japan Found Cancer Res ヒトプロヒビチンおよびそれをコードするｄｎａ
US5861301A (en) 1992-02-20 1999-01-19 American Cayanamid Company Recombinant kinase insert domain containing receptor and gene encoding same
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
JPH07507689A (ja) 1992-06-08 1995-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 特定組織のターゲティング方法及び組成物
WO1993025698A1 (en) 1992-06-10 1993-12-23 The United States Government As Represented By The Vector particles resistant to inactivation by human serum
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
US5811098A (en) 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US6340674B1 (en) 1993-03-26 2002-01-22 Thomas Jefferson University Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides
WO1994022486A1 (en) 1993-03-26 1994-10-13 Thomas Jefferson University Method of inhibiting the proliferation and causing the differentiation of cells with igf-1 receptor antisense oligonucleotides
EP0695169B1 (de) 1993-04-22 2002-11-20 SkyePharma Inc. Multivesikuläre liposomen mit verkapseltem cyclodextrin und pharmakologisch wirksamen verbindungen sowie verfahren zu deren verwendung
ATE304604T1 (de) 1993-06-24 2005-09-15 Frank L Graham Adenovirus vektoren für gentherapie
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
EP0711829A3 (de) 1993-09-15 1997-07-09 Viagene Inc Rekombinanter Alphavirus Vektor
DE69434594T2 (de) 1993-10-25 2006-09-21 Canji, Inc., San Diego Rekombinante adenoviren-vektor und verfahren zur verwendung
JP3002702B2 (ja) 1993-11-16 2000-01-24 スカイファーム インコーポレーテッド 活性物質の制御放出を有する小胞
US6696548B2 (en) 1993-12-03 2004-02-24 St. Jude Children's Research Hospital Antibodies for recognition of alk protein tyrosine/kinase receptor
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
US6045797A (en) 1994-03-14 2000-04-04 New York University Medical Center Treatment or diagnosis of diseases or conditions associated with a BLM domain
AU2187595A (en) 1994-03-14 1995-10-03 New York University Medical Center Methods for treatment or diagnosis of diseases or conditions associated with abnormal signal transduction
US5837523A (en) 1994-05-05 1998-11-17 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
JP4303315B2 (ja) 1994-05-09 2009-07-29 オックスフォード バイオメディカ（ユーケー）リミテッド 非交差性レトロウイルスベクター
US5770567A (en) 1994-11-14 1998-06-23 Genentech, Inc. Sensory and motor neuron derived factor (SMDF)
HRP950558A2 (en) 1994-11-15 1997-12-31 Scott M. Wilhelm Substituted 4-biarylbutric or biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5783404A (en) 1995-04-13 1998-07-21 Amgen Inc. Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
US5663144A (en) 1995-05-03 1997-09-02 The Trustees Of The University Of Pennsylvania Compounds that bind to p185 and methods of using the same
US6008373A (en) * 1995-06-07 1999-12-28 Carnegie Mellon University Fluorescent labeling complexes with large stokes shift formed by coupling together cyanine and other fluorochromes capable of resonance energy transfer
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
EP0861267A4 (de) 1995-11-14 2000-02-02 Univ Jefferson Induktion und resistenz gegen tumorwachstum mittels loeslichem igf-1
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
AU2998597A (en) 1996-05-06 1997-11-26 Chiron Corporation Crossless retroviral vectors
US6413730B1 (en) 1996-07-05 2002-07-02 Mount Sinai Hospital Corporation Method for identifying compounds that inhibit or enhance activation of a transmembrane ligand for a receptor tyrosine kinase
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
US5878712A (en) * 1996-09-20 1999-03-09 Fev Motorentechnik Gmbh & Co. Kg System for the direct injection of fuel in internal-combustion engines
ATE343400T1 (de) 1996-09-24 2006-11-15 Merck & Co Inc Verbindungen zur hemmung der angiogenese durch gentherapie
US5910583A (en) 1996-11-04 1999-06-08 Duke University Antisense oligonucleotides against ERBB-2
US7125969B1 (en) 1996-11-27 2006-10-24 The Regents Of The University Of California ETS-related gene overexpressed in human breast and epithelial cancers
US20020172965A1 (en) * 1996-12-13 2002-11-21 Arcaris, Inc. Methods for measuring relative amounts of nucleic acids in a complex mixture and retrieval of specific sequences therefrom
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO1998058053A1 (en) 1997-06-18 1998-12-23 Merck & Co., Inc. Human receptor tyrosine kinase, kdr
US5877171A (en) * 1997-07-28 1999-03-02 Mcleod; Malcolm N. Method of treating pre-menstrual syndrome using chromium
CA2306451A1 (en) 1997-10-15 1999-04-22 Abbott Laboratories Methods and compositions for detecting hepatitis e virus
ATE438720T1 (de) 1998-02-04 2009-08-15 Genentech Inc Verwendung des heregulins als epithelzellenwachstumsfaktor
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
EP1308455B9 (de) 1998-05-06 2006-06-14 Genentech, Inc. Anti-HER2 Antikörperzusammensetzung
US7105639B2 (en) 1998-05-15 2006-09-12 Genentech, Inc. Anti-PRO 4405 antibodies
JP2002517241A (ja) 1998-06-11 2002-06-18 アストラゼネカ アクチボラグ ヒト受容体チロシンキナーゼ
US7173005B2 (en) 1998-09-02 2007-02-06 Antyra Inc. Insulin and IGF-1 receptor agonists and antagonists
US6875741B2 (en) 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
CA2345899A1 (en) 1998-11-07 2000-05-18 Genentech, Inc. Method for enhancing proliferation of inner ear hair cells using ligands for her2 and/or her3 receptors
US6541214B1 (en) 1998-11-13 2003-04-01 Oregon Heath Science University N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
US6337338B1 (en) 1998-12-15 2002-01-08 Telik, Inc. Heteroaryl-aryl ureas as IGF-1 receptor antagonists
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7396810B1 (en) 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
US7393823B1 (en) * 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
WO2000069909A1 (en) 1999-05-14 2000-11-23 The United States Of America Through The Department Of Veterans Affairs Isolation and characterization of epidermal growth factor related protein
WO2001001748A2 (en) 1999-07-02 2001-01-11 Genentech, Inc. Peptide compounds that bind her2
EP1226441A4 (de) 1999-10-15 2003-08-06 Human Genome Sciences Inc Polynukleotide, polypeptide und antikörper des protein-tyrosin-kinaserezeptors
AU2229901A (en) * 1999-12-28 2001-07-09 Sumitomo Pharmaceuticals Company, Limited Preventives and remedies for chronic hepatitis
CN1447696A (zh) 2000-05-19 2003-10-08 杰南技术公司 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
TWI317285B (en) 2000-07-28 2009-11-21 Dainippon Sumitomo Pharma Co New use and kit for remedies for cancer
AU9500201A (en) 2000-08-09 2002-02-18 Imclone Systems Inc Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
AU2001281254A1 (en) 2000-08-10 2002-02-18 Pharmacia Corporation A new egf motif repeat protein obtained from a cdna library from hs-5 stromal cell line
US6818424B2 (en) * 2000-09-01 2004-11-16 E. I. Du Pont De Nemours And Company Production of cyclic terpenoids
US6686940B2 (en) * 2000-11-16 2004-02-03 Minolta Co., Ltd. Reversible image display medium
EP1228766A1 (de) 2001-01-31 2002-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PYK2 Phosphorylierung durch HER3 induziert Tumorinvasion
US20020104642A1 (en) * 2001-02-05 2002-08-08 Garner Scott D. Heat pipe system for heat reduction in automobiles
US7213546B2 (en) * 2001-03-21 2007-05-08 Steven Vermeer Engine airflow management system
WO2002090991A2 (en) 2001-05-03 2002-11-14 Oxford Glycosciences (Uk) Ltd Proteins and genes for diagnosis and treatment of erbb2-related cancer
US20030124513A1 (en) 2001-05-29 2003-07-03 Mcswiggen James Enzymatic nucleic acid treatment of diseases or conditions related to levels of HIV
US7125680B2 (en) 2001-07-27 2006-10-24 The Regents Of The University Of California Methods and materials for characterizing and modulating interaction between heregulin and HER3
US20040002071A1 (en) 2001-09-19 2004-01-01 Intergenetics, Inc. Genetic analysis for stratification of cancer risk
AU2002353891A1 (en) 2001-10-25 2003-05-06 Buck Institute For Age Research Screening system for modulators of her2 mediated transcription and her2 modulators identifed thereby
US7200845B2 (en) * 2001-12-03 2007-04-03 Hewlett-Packard Development Company, L.P. System and method for high availability firmware load
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
EP1569689A4 (de) 2002-01-18 2009-08-05 Novartis Vaccines & Diagnostic Il2/anti-her2-antikörper-kombinationstherapie gegen krebs, der gekennzeichnet ist durch überexpression des her2-rezeptor-proteins
JP2005522514A (ja) 2002-04-10 2005-07-28 ジェネンテック・インコーポレーテッド 抗ｈｅｒ２抗体改変体
HUP0600340A3 (en) 2002-07-15 2011-06-28 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
WO2004041065A2 (en) 2002-10-30 2004-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services METHODS FOR PROPHYLAXIS AND TREATMENT OF HER-2/neu TUMORS
EP1418527A1 (de) * 2002-11-08 2004-05-12 Motorola, Inc. Haltevorrichtung für mehrere SIM-Karten
TW200420565A (en) 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
SE0203747D0 (sv) 2002-12-18 2002-12-18 Karolinska Innovations Ab New use
SE0203746D0 (sv) 2002-12-18 2002-12-18 Karolinska Innovations Ab New compounds
US7009714B2 (en) * 2003-02-26 2006-03-07 Hitachi High-Technologies Corporation Method of dry etching a sample and dry etching system
WO2005016966A2 (en) 2003-05-16 2005-02-24 Receptor Biologix, Inc. Intron fusion proteins, and methods of identifying and using same
CN100392074C (zh) 2003-10-15 2008-06-04 上海海欣生物技术有限公司 树突状细胞肿瘤疫苗及其制法和用途
EP1796711A2 (de) 2004-04-22 2007-06-20 Oregon Health and Science University Herstatin oder seine intron-8-kodierte domäne zur modulierung der durch igf-1-rezeptor und erbb-rezeptoren vermittelten signalisierung
WO2006042002A2 (en) 2004-10-05 2006-04-20 Oregon Health And Science University Compositions and methods for treating disease
US7251756B2 (en) * 2005-04-26 2007-07-31 International Business Machines Corporation Method and apparatus for increasing fuse programming yield through preferred use of duplicate data
US9018286B2 (en) * 2012-05-24 2015-04-28 Sabic Global Technologies B.V. Flame retardant polycarbonate compositions, methods of manufacture thereof and articles comprising the same

Also Published As

Publication number Publication date
EP1257822B1 (de) 2012-01-18
US7625859B1 (en) 2009-12-01
US20080219997A1 (en) 2008-09-11
EP1257822A4 (de) 2004-09-08
WO2001061356A9 (en) 2002-10-31
US7935784B2 (en) 2011-05-03
AU4157501A (en) 2001-08-27
CA2400473A1 (en) 2001-08-23
WO2001061356A1 (en) 2001-08-23
US20100267027A1 (en) 2010-10-21
EP1257822A1 (de) 2002-11-20
US20120045755A1 (en) 2012-02-23
JP2004501605A (ja) 2004-01-22

Similar Documents

Publication Publication Date Title
RU2214267C2 (ru) Пептидный антагонист зонулина
AU4157501A (en) Her-2 binding antagonists
DK0758383T3 (da) Oplöselige polypeptidfraktioner af LAG-3-proteinet; fremgangsmåde til fremstilling; terapeutisk sammensætning; antiidiotypisk antistof
ES2187946T3 (es) Uso de interleucina-15.
McKeehan et al. Heparan sulfate fibroblast growth factor receptor complex: Structure‐function relationships
CA2361181A1 (en) Her-2 binding antagonists
WO2001085790A3 (en) Mammalian cytokine receptor subunit proteins, related reagents and methods
WO2001090358A3 (en) Mammalian receptor proteins; related reagents and methods
WO2005087811A3 (en) Estrogen receptors and methods of use
WO2001036467A3 (en) Mammalian receptor proteins; related reagents and methods
WO2000023565A3 (en) Novel neuropilin/growth factor binding and uses thereof
KR980002066A (ko) 변이형 인간 성장호르몬 및 그의 용도
WO1999046379A3 (en) Human receptor proteins; related reagents and methods
EP0992584A3 (de) Gereinigte Säugetier FLT3 Liganden und deren Agonisten und Antagonisten
GB2342652A (en) Polypeptides comprising a coiled-coil and an addition
ATE294816T1 (de) Neue, physiologisch aktive peptide und ihre verwendung.
ATE190318T1 (de) Pcna bindende substanz
HK1044023A1 (zh) Ox2受体同系物
WO1999048908A3 (fr) POLYPEPTIDE IMMUNOREACTIF DU RECEPTEUR TrkA du NGF ET UTILISATIONS
AR018045A1 (es) Proteina placentaria 13 y polipetido, molecula de adn que los codifica, anticuerpos capaces de enlazarse a ellos, metodo para la deteccion decomplicaciones relacionadas con el embarazo, metodo recombinante para la produccion de dicha proteina y un equipo para el diagnostico de complicacionesrelacion
WO1992016623A3 (en) Receptors for bombesin-like peptides
CA2180957A1 (en) Cloning and recombinant production of crf receptor(s)
WO2000017363A3 (en) Interleukin-1 like molecule: interleukin-1-zeta; nucleic acids, polypeptides, antibodies, their uses
BR0011802A (pt) Proteìna citoplasmática de ligação de cálcio induzida por trauma de cabeça
Mason et al. A highly conserved surface loop in the C-terminal domain of ovotransferrin (residues 570-584) is remote from the receptor-binding site